Compositions and methods for treating hypertension by modulating endocrine activity
Disclosed herein are compounds and ligands, and antihypertensive compositions formed therewith, that modulate seminal endocrine factors that control blood pressure and, thereby, treat hypertension. Also disclosed herein are methods for using the antihypertensive compositions to treat hypertension and disorders associated therewith.
1. A composition for treating hypertension of a patient, comprising:
propionic acid and butyrate, said propionic acid comprising an EC 50 value in the range of from about 0.05 μM to about 0.5 μM, said butyrate comprising an EC 50 value in the range of from about 0.01 μM to about 0.3 μM,
said composition adapted to induce at least 50% activation of olfactory receptor family 51 subfamily E member 1 (OR51E1), olfactory receptor family 51 subfamily E member 2 (OR51E2), free fatty acid receptor 2 (FFAR2), free fatty acid receptor 3 (FFAR3) and hydroxycarboxylic acid receptor 2 (GPR109A) in vivo, whereby secretion of serotonin (5-HT), secretin, prostaglandin E 2 and vasoactive intestinal protein (VIP), and attenuated secretion of nuclear factor κ-B (NK-κB) and NADPH Oxidases (NOXs) are induced,
wherein said secretion of serotonin (5-HT), secretin, prostaglandin E 2 and VIP is sufficient to induce vasodilation of arterial vasculature of said patient, and said attenuated secretion of said NK—κB and NOXs is sufficient to abate renin secretion.
2. The composition of claim 1 , wherein said EC 50 value of said propionic acid in said composition is in the range of from about 0.1 μM to about 0.2 μM.
3. The composition of claim 1 , wherein said EC 50 value of said butyrate in said composition is in the range of from about 0.01 μM to about 0.02 μM.
4. The composition of claim 1 , wherein said composition further comprises acetate.
5. The composition of claim 4 , wherein said acetate comprises an EC 50 value in said composition in the range of from about 0.01 μM to about 0.3 μM.